Promontory Therapeutics
Führungskräfte
Siehe das Organigramm mit seine 16 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Promontory Therapeutics
- Robert Fallon, Chairman, President and Chief Executive Officer
- Charles Stuckey, Director
- Neil Sunderland, Director
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Promontory Therapeutics nachzuverfolgen.
Biotechnologie
Promontory Therapeutics hat 2.285 Konkurrenten , einschließlich Lonza (Schweiz), Eurofins (Luxemburg) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Karius hat gerade eine Spendenaktion von 100 Millionen Dollar angekündigt. (veröffentlicht am 3, Mai 2024).
- Transcarent hat gerade eine Spendenaktion von 126 Millionen Dollar angekündigt. (veröffentlicht am 2, Mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (veröffentlicht am 2, Mai 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Promontory Therapeutics
- Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects | Promontory Therapeutics | Advancing small molecule immunotherapy
- The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup" | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics to Present Data on PT-112 Mechanism of Action at the Society for Immunotherapy of Cancer's 38th Annual Meeting | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors | Promontory Therapeutics | Advancing small molecule immunotherapy
- View more press releases Close
Social media about Promontory Therapeutics
- Promontory Therapeutics auf Wikipedia, Google News & Yahoo Finance
- Promontory Therapeutics auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Peter Espig, per E-Mail kontaktieren. 
Promontory Therapeutics unter +1 646... anrufen
